CA2944573C - Combinations of cancer therapeutics - Google Patents
Combinations of cancer therapeutics Download PDFInfo
- Publication number
- CA2944573C CA2944573C CA2944573A CA2944573A CA2944573C CA 2944573 C CA2944573 C CA 2944573C CA 2944573 A CA2944573 A CA 2944573A CA 2944573 A CA2944573 A CA 2944573A CA 2944573 C CA2944573 C CA 2944573C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- her2
- cancer
- acceptable salts
- physiologically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461974765P | 2014-04-03 | 2014-04-03 | |
| US61/974,765 | 2014-04-03 | ||
| PCT/EP2015/000525 WO2015149909A1 (en) | 2014-04-03 | 2015-03-09 | Combinations of cancer therapeutics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2944573A1 CA2944573A1 (en) | 2015-10-08 |
| CA2944573C true CA2944573C (en) | 2022-10-25 |
Family
ID=52692591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2944573A Active CA2944573C (en) | 2014-04-03 | 2015-03-09 | Combinations of cancer therapeutics |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9980966B2 (enExample) |
| EP (1) | EP3125935B1 (enExample) |
| JP (1) | JP6629753B2 (enExample) |
| KR (1) | KR102410696B1 (enExample) |
| CN (1) | CN106456752B (enExample) |
| AR (1) | AR099931A1 (enExample) |
| AU (1) | AU2015240094B2 (enExample) |
| CA (1) | CA2944573C (enExample) |
| ES (1) | ES2768900T3 (enExample) |
| IL (1) | IL248126A0 (enExample) |
| MX (1) | MX370540B (enExample) |
| NZ (1) | NZ725361A (enExample) |
| RU (1) | RU2733401C2 (enExample) |
| SG (1) | SG11201608189WA (enExample) |
| WO (1) | WO2015149909A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL302951A (en) * | 2020-11-16 | 2023-07-01 | Merck Patent Gmbh | Kinase inhibitor combinations for cancer treatment |
| AU2025220299A1 (en) * | 2024-02-05 | 2026-07-16 | Evexta Bio | Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| US7547794B2 (en) | 2003-04-03 | 2009-06-16 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| US7189729B2 (en) | 2003-09-30 | 2007-03-13 | Irm Llc | Methods and compositions as protein kinase inhibitors |
| US7816353B2 (en) | 2003-10-24 | 2010-10-19 | Exelixis, Inc. | P70S6 kinase modulators and method of use |
| RU2006121646A (ru) | 2003-11-21 | 2008-01-10 | Новартис АГ (CH) | Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы |
| BRPI0417498A (pt) | 2003-12-09 | 2007-05-29 | Us Gov Health & Human Serv | método para suprimir uma resposta imune em um indivìduo; método de inibição da proliferação de um célula; método de tratamento de um distúrbio proliferativo em um indivìduo; método para selecionar um agente imunossupressor ou anti-proliferativo; composição farmacêutica e estente vascular |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| AU2005322085B2 (en) | 2004-12-28 | 2012-07-19 | Exelixis, Inc. | [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
| US8343953B2 (en) | 2005-06-22 | 2013-01-01 | Astex Therapeutics Limited | Pharmaceutical compounds |
| CN101300029A (zh) * | 2005-11-04 | 2008-11-05 | 惠氏公司 | mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合 |
| UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| KR101699991B1 (ko) | 2009-02-11 | 2017-01-26 | 메르크 파텐트 게엠베하 | 신규의 아미노 아자헤테로시클릭 카르복사미드 |
| US9932403B2 (en) | 2010-05-20 | 2018-04-03 | Ablynx Nv | Biological materials related to HER3 |
| UA110113C2 (xx) | 2010-07-29 | 2015-11-25 | Біциклічні азагетероциклічні карбоксаміди | |
| EA023821B1 (ru) * | 2010-11-24 | 2016-07-29 | Мерк Патент Гмбх | Хиназолинкарбоксамидазетидины, их применение в лечении гиперпролиферативных заболеваний и содержащие их композиции |
| MX370448B (es) | 2013-03-11 | 2019-12-13 | Merck Patent Gmbh | Derivados de 6- [4- (1h-imidazol-2-il) piperidin-1-il] pirimidin-4-amina como moduladores de la actividad de cinasa. |
-
2015
- 2015-03-09 NZ NZ725361A patent/NZ725361A/en unknown
- 2015-03-09 JP JP2016560799A patent/JP6629753B2/ja active Active
- 2015-03-09 KR KR1020167030676A patent/KR102410696B1/ko active Active
- 2015-03-09 SG SG11201608189WA patent/SG11201608189WA/en unknown
- 2015-03-09 CN CN201580018245.XA patent/CN106456752B/zh active Active
- 2015-03-09 MX MX2016012825A patent/MX370540B/es active IP Right Grant
- 2015-03-09 RU RU2016143153A patent/RU2733401C2/ru active
- 2015-03-09 EP EP15710714.5A patent/EP3125935B1/en active Active
- 2015-03-09 AU AU2015240094A patent/AU2015240094B2/en active Active
- 2015-03-09 WO PCT/EP2015/000525 patent/WO2015149909A1/en not_active Ceased
- 2015-03-09 CA CA2944573A patent/CA2944573C/en active Active
- 2015-03-09 ES ES15710714T patent/ES2768900T3/es active Active
- 2015-03-09 US US15/128,045 patent/US9980966B2/en active Active
- 2015-04-01 AR ARP150100982A patent/AR099931A1/es unknown
-
2016
- 2016-09-29 IL IL248126A patent/IL248126A0/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP6629753B2 (ja) | 2020-01-15 |
| RU2016143153A3 (enExample) | 2018-10-17 |
| EP3125935B1 (en) | 2019-10-23 |
| WO2015149909A1 (en) | 2015-10-08 |
| NZ725361A (en) | 2022-09-30 |
| US9980966B2 (en) | 2018-05-29 |
| CA2944573A1 (en) | 2015-10-08 |
| MX2016012825A (es) | 2017-01-05 |
| AU2015240094B2 (en) | 2020-07-30 |
| SG11201608189WA (en) | 2016-10-28 |
| ES2768900T3 (es) | 2020-06-24 |
| AU2015240094A1 (en) | 2016-11-17 |
| AR099931A1 (es) | 2016-08-31 |
| KR102410696B1 (ko) | 2022-06-17 |
| JP2017509683A (ja) | 2017-04-06 |
| MX370540B (es) | 2019-12-17 |
| RU2733401C2 (ru) | 2020-10-01 |
| BR112016020135A8 (pt) | 2021-07-06 |
| EP3125935A1 (en) | 2017-02-08 |
| US20170100402A1 (en) | 2017-04-13 |
| CN106456752A (zh) | 2017-02-22 |
| KR20160133005A (ko) | 2016-11-21 |
| IL248126A0 (en) | 2016-11-30 |
| BR112016020135A2 (pt) | 2017-08-15 |
| CN106456752B (zh) | 2020-11-20 |
| RU2016143153A (ru) | 2018-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014224976B2 (en) | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents | |
| EP3288558A1 (en) | Combinations of inhibitors of irak4 with inhibitors of btk | |
| AU2013234767B2 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds | |
| AU2015240094B2 (en) | Combinations of cancer therapeutics | |
| CA3109184A1 (en) | Treatment of b cell malignancies | |
| US20230405118A1 (en) | Stat-activated macrophages, compositions, and uses thereof | |
| EP3585437B1 (en) | Combinations of copanlisib with anti-pd-1 antibody | |
| AU2021292433A1 (en) | TLR7/8 antagonists and uses thereof | |
| BR112016020135B1 (pt) | Mistura de compostos, seus usos, composição farmacêutica, e conjunto (kit) | |
| AU2021303438B2 (en) | Combination of a methionine aminopeptidase 2 inhibitor and VEGFR/VEGF inhibitor | |
| US20240382495A1 (en) | Combinations of copanlisib with anti-pd-1 antibody | |
| RU2854156C1 (ru) | Комбинация ингибитора метионин аминопептидазы-2 и ингибитора рфрэс/фрэс | |
| US20240024324A1 (en) | Kinase inhibitor combinations for cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200304 |